Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions

Familial Partial Lipodystrophy

Interventions

DRUG

Obeticholic Acid

Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .

DRUG

Placebo

Identical to Obeticholic Acid - placebo drug

Trial Locations (2)

UT Southwestern Medical Center, Dallas

UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas

All Listed Sponsors

lead

Abhimanyu Garg

OTHER

NCT02430077 - Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients | Biotech Hunter | Biotech Hunter